300255.SZ
常山药业
SZSE · Healthcare · C 制造业 · CN
CNY 23.38
−4.69%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 872.5M | 875.1M | 1.0B | 1.4B | 2.3B |
| Cost of Revenue | 736.9M | 742.7M | 864.8M | 1.1B | 1.3B |
| Gross Profit | 135.6M | 132.4M | 166.0M | 317.4M | 1.0B |
| Operating Expenses | |||||
| R&D Expense | 31.1M | 34.1M | 47.2M | 158.8M | 145.0M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 139.8M | 136.9M | 130.3M | 166.5M | 133.1M |
| Selling & Marketing Expense | 48.0M | 49.6M | 90.0M | 472.8M | 613.6M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 327.5M | 325.4M | 382.1M | 912.2M | 1.0B |
| Cost and Expenses | 1.1B | 1.1B | 1.2B | 2.0B | 2.3B |
| Operating Income (EBIT) | (348.5M) | (350.3M) | (254.0M) | (1.2B) | 20.5M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (354.1M) | (355.9M) | (257.1M) | (1.2B) | 18.1M |
| Income Tax Expense | 11.6M | 11.6M | 7.0M | 16.5M | 8.0M |
| Bottom Line | |||||
| Net Income | (355.8M) | (357.9M) | (249.5M) | (1.2B) | 17.5M |
| Earnings from Cont. Ops | (365.7M) | (367.5M) | (264.0M) | (1.2B) | 10.2M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (355.8M) | (357.9M) | (249.5M) | (1.2B) | 17.5M |
| Per Share | |||||
| Basic EPS | (CN¥0.39) | (CN¥0.39) | (CN¥0.27) | (CN¥1.35) | CN¥0.02 |
| Diluted EPS | (CN¥0.39) | (CN¥0.39) | (CN¥0.27) | (CN¥1.35) | CN¥0.02 |
| Revenue Per Share | CN¥0.95 | CN¥0.95 | CN¥1.12 | CN¥1.54 | CN¥2.67 |
| Shares | |||||
| Basic Shares Outstanding | 917.3M | 917.7M | 924.0M | 918.7M | 875.7M |
| Diluted Shares Outstanding | 917.3M | 917.7M | 924.0M | 918.7M | 875.7M |
| Profitability Metrics | |||||
| EBITDA | — | (280.8M) | (180.6M) | (1.2B) | 78.0M |
| D&A | — | 69.5M | 73.4M | 75.2M | 57.6M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026